Mediator release is altered in immunotherapy-treated patients: A 4-year study

被引:0
作者
Dokic, D [1 ]
Nethe, A [1 ]
KleineTebbe, J [1 ]
Kunkel, G [1 ]
Baumgarten, CR [1 ]
机构
[1] FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT CLIN IMMUNOL & ASTHMA, OPD, D-13353 BERLIN, GERMANY
关键词
immunotherapy; mediator release; specific IgG antibodies;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
In recent years, it has been possible to demonstrate mediator release into the nasal secretion after nasal allergen challenge in patients with allergic rhinitis. Using the nasal provocation model, we determined whether the mediator release was altered in immunotherapy-treated patients. Seventeen grass-pollen-allergic patients were examined under controlled, reproducible conditions. Serial challenges with increasing doses of grass pollen produced increasing numbers of clinical symptoms and release of mediators such as kinins, TAME-esterase activity and histamine. Ten patients received a semidepot perennial grass-pollen extract for 4 years. Seven patients served as controls and did not receive immunotherapy during the observation period. Data from the group of patients receiving immunotherapy over the first year already showed a partially significant decline in the maximal mediator release after nasal allergen challenges compared to the results of pretreated challenges, whereas controls did not show any significant changes. Nasal allergen challenges after termination of 4 years' immunotherapy significantly modified the mediator release compared to pretreatment values (TAME-esterase activity P < 0.05, kinins P < 0.01, and histamine P < 0.01). Decrease of mediator release paralleled the symptom-medication scores and quantitative skin prick test. Finally, we could demonstrate a significant correlation between specific IgG increase and mediator decrease in the treated group.
引用
收藏
页码:796 / 803
页数:8
相关论文
共 45 条
[41]   Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1 [J].
Vassilaros, Stamatis ;
Tsibanis, Anastasios ;
Tsikkinis, Annivas ;
Pietersz, Geoffrey A. ;
McKenzie, Ian F. C. ;
Apostolopoulos, Vasso .
IMMUNOTHERAPY, 2013, 5 (11) :1177-1182
[42]   Phoenix sylvestris Roxb pollen allergy:: A 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India [J].
Chakraborty, P. ;
Roy, I. ;
Chatterjee, S. ;
Chanda, S. ;
Gupta-Bharracharya, S. .
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2006, 16 (06) :377-384
[43]   Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study [J].
Zhang, Hai ;
He, Haiquan ;
Feng, Qingyi ;
Wu, Bomeng ;
Chen, Ying ;
Zhang, Zhenyang ;
Zhou, Linrong ;
Li, Cui ;
Lin, Wanli ;
Lin, Jiangbo .
FRONTIERS IN ONCOLOGY, 2025, 14
[44]   CD4 TIL (TUMOR-INFILTRATING LYMPHOCYTES) INDUCE COMPLETE RESPONSE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA PREVIOUSLY TREATED WITH IL-2 - A PRELIMINARY-STUDY [J].
THIOUNN, N ;
MATHIOT, C ;
FLAM, T ;
TARTOUR, E ;
PEYRET, C ;
JOYEUX, I ;
ABECASSIS, JP ;
ZERBIB, M ;
FRIDMAN, WH ;
DEBRE, B .
JOURNAL D UROLOGIE, 1994, 100 (04) :185-188
[45]   Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients [J].
Nakamura, Yasuhiro ;
Namikawa, Kenjiro ;
Kiniwa, Yukiko ;
Kato, Hiroshi ;
Yamasaki, Osamu ;
Yoshikawa, Shusuke ;
Maekawa, Takeo ;
Matsushita, Shigeto ;
Takenouchi, Tatsuya ;
Inozume, Takashi ;
Nakai, Yasuo ;
Fukushima, Satoshi ;
Saito, Shintaro ;
Otsuka, Atsushi ;
Fujimoto, Noriki ;
Isei, Taiki ;
Baba, Natsuki ;
Matsuya, Taisuke ;
Tanaka, Ryo ;
Kaneko, Takahide ;
Onishi, Masazumi ;
Kuwatsuka, Yutaka ;
Nagase, Kotaro ;
Onuma, Takehiro ;
Nomura, Motoo ;
Umeda, Yoshiyasu ;
Yamazaki, Naoya .
EUROPEAN JOURNAL OF CANCER, 2022, 176 :78-87